New Leaf Venture Partners

VC New York, United States · Founded 2005

New Leaf Venture Partners focuses exclusively on healthcare technology, investing across biopharmaceuticals, information convergence (healthcare IT and data), life science tools, and select medical devices. They partner with management teams from company creation through public and private growth-stage markets.

About New Leaf Venture Partners

New Leaf Venture Partners is a long-tenured US healthcare venture firm with a focus on later-stage biopharma and medical device investing, often participating in crossover and pre-IPO rounds. The firm’s history places it among the established healthcare-dedicated venture investors with a strong network across pharma, biotech, and the public capital markets. Healthcare exposure is total. AI focus is selective and outcome-driven; the firm will fund AI-enabled healthcare companies where the model demonstrably accelerates clinical or commercial outcomes, but it is not a thesis investor in AI for its own sake. Stage is typically Series B through pre-IPO, with check sizes plausibly in the USD 10M to USD 30M range, often as part of crossover syndicates that include public-market specialists. This is the wrong door for pre-revenue, seed, or research-stage companies, and for healthcare software founders without a clear path to public-market readiness. It is a strong fit for revenue-stage or late-clinical-stage healthcare companies preparing for crossover financings, IPOs, or strategic exits, particularly in biopharma and devices. Entry path is a warm introduction from a banker, prior portfolio CEO, or co-investing crossover fund; cold outreach is unlikely to advance given the late-stage focus and the importance of capital-markets relationships. Bring audited financials, a clean cap table, a clear clinical or commercial milestone path, and a credible IPO or strategic exit thesis.

Founder reviews

No founder reviews yet. Raised from this fund? Share your experience with other founders.

Healthcare AI tools backed by New Leaf Venture Partners

Tools made by companies in New Leaf Venture Partners's portfolio that we cover in the directory.

Cleerly LABS
Cleerly
Cardiology AI
Cleerly LABS is an AI-powered, FDA-cleared web-based software for comprehensive analysis of coronary CT angiography (CCTA) to detect, quantify, and characterize atherosclerosis and stenosis, aiding in personalized heart disease management.
Cleerly ISCHEMIA
Cleerly
Cardiology AI
Cleerly ISCHEMIA is an FDA-cleared AI tool that analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease.
Zio ECG Utilization Software (ZEUS) System
iRhythm Technologies
Cardiology AI
The Zio ECG Utilization Software (ZEUS) System by iRhythm Technologies is an AI-powered, cloud-based platform that analyzes continuous ECG data from wearable Zio monitors to aid physicians in the diagnosis and management of cardiac arrhythmias.
ZEUS System
iRhythm Technologies
Cardiology AI
The ZEUS System by iRhythm Technologies is an AI-powered software that analyzes ECG data from wearable biosensors for long-term continuous cardiac monitoring, aiding in the detection and characterization of arrhythmias like Atrial Fibrillation.
ZEUS System (Zio Watch)
iRhythm Technologies
Cardiology AI
iRhythm Technologies' ZEUS System (Zio Watch) is an FDA-cleared, AI-powered wearable for long-term continuous cardiac monitoring, specifically designed to detect and characterize Atrial Fibrillation (AFib) and other cardiac arrhythmias, providing actionable insights for physicians.
Zio AT ECG Monitoring System
iRhythm Technologies, Inc.
Cardiology AI
The Zio AT ECG Monitoring System by iRhythm Technologies is an FDA-cleared, wearable mobile cardiac telemetry (MCT) service offering continuous, AI-powered ECG monitoring for long-term arrhythmia detection and comprehensive reporting.
Zio XT ECG Monitoring System
iRhythm Technologies
Cardiology AI
The Zio XT ECG Monitoring System by iRhythm Technologies offers a wearable, single-lead ECG biosensor for up to 14 days of continuous cardiac monitoring, utilizing FDA-cleared AI and expert review for accurate arrhythmia detection and diagnosis.
Kyruus Health Check-In
Kyruus Health
Patient Engagement & Education
Kyruus Health Check-In provides a HIPAA-compliant digital patient intake and engagement solution, replacing paper forms with an interactive, remote pre-visit process that captures demographics, clinicals, consent, insurance, and payments, and seamlessly integrates with major EHRs.
AiCure (H. Code)
AiCure
Drug Discovery & Research
AiCure's H.Code is an AI-powered platform using computer vision and predictive analytics to verify and improve medication and clinical behavior adherence in clinical trials and healthcare settings.
TigerConnect
TigerConnect
Medical Phone & Communication
TigerConnect provides a HIPAA-compliant clinical communication and collaboration platform with secure messaging, voice, and video, widely used by hospitals and healthcare systems to unify workflows and accelerate care delivery.
Cleerly
Cleerly
Cardiology AI
Cleerly is an FDA-cleared AI platform that analyzes coronary CT scans to quantify plaque volume, characterize plaque morphology, and assess ischemia.

Portfolio companies in our directory

Other portfolio companies

Companies in New Leaf Venture Partners's portfolio not currently in our directory.

Team

Ron Hunt
Co-Founder / Managing Director
LinkedIn
Vijay Lathi
Co-Founder / Managing Director
LinkedIn
Craig Slutzkin
Chief Operating Officer / Chief Financial Officer
LinkedIn
Anthony Ford
Senior Advisor
LinkedIn

Pitch / review this investor

Have you raised from New Leaf Venture Partners? Founders only — share your honest experience (anonymous OK, moderated before publishing).

Share your experience
Last updated 2026-05-06. Sourced from this fund's published materials.
AI Tool Finder
AI-powered search. Results may not be comprehensive.